Revision as of 08:11, 26 August 2024 edit Noxoug1 (talk \| contribs) Extended confirmed users, New page reviewers 5,704 edits →LysaKare Tag: Visual edit ← Previous edit		Revision as of 08:17, 26 August 2024 edit undo Noxoug1 (talk \| contribs) Extended confirmed users, New page reviewers 5,704 edits →LysaKare Tag: Visual edit: Switched Next edit →
Line 194: === LysaKare === LysaKare received a marketing authorisation valid throughout the EU on 25 July 2019.<ref name="LysaKare EPAR">{{~~Cite~~cite web \| title=LysaKare EPAR \| website=[[European Medicines Agency]] (EMA) \| date=26 August 2024 \| url=https://www.ema.europa.eu/en/medicines/human/EPAR/lysakare \|~~website~~ access-date=~~EMA~~26 August 2024 \| url-status=live }}{{PD-notice}}</ref> LysaKare protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (177Lu) oxodotreotide. LysaKare is for use in adults and contains the active substances arginine and lysine.<ref name="LysaKare EPAR"/> ==Pipeline==

Advanced Accelerator Applications: Difference between revisions